Paladin Partners’s MiNK Therapeutics INKT Stock Holding History

Paladin Partners’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.7K	Hold	1,000	–	–	0.01%	131
2026 Q1	$10.5K	Hold	1,000	–	–	0.01%	128
2025 Q4	$11.2K	Buy	+1,000	New	+$12.9K	0.01%	127

Other funds holding INKT

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return

Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Paladin Partners's INKT Position: Q2 2026 in Review

Paladin Partners held its MiNK Therapeutics (INKT) position steady in Q2 2026 at 1,000 shares worth $11.7K. The position accounts for 0.01% of the portfolio, ranked #131.

Paladin Partners first reported a position in INKT in Q4 2025 and has held it in 3 quarters since. 27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

Paladin Partners held 1,000 shares of MiNK Therapeutics worth $11.7K as of Q2 2026.
Paladin Partners left its MiNK Therapeutics share count unchanged in Q2 2026.
MiNK Therapeutics made up 0.01% of Paladin Partners's portfolio in Q2 2026, its #131 holding.
Paladin Partners first reported a position in MiNK Therapeutics in Q4 2025 and has held it in 3 quarters since.
27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Paladin Partners's 13F filing for Q2 2026, filed 7 Aug 2026.